Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) is advancing a novel approach to cancer treatment that could reshape how DNA repair pathways are targeted. In a recent BioMedWire podcast, Chief Medical Officer Dr. Islam Mohamed discussed the company's lead drug candidate, ONC010, which targets the DNA repair enzyme polynucleotide kinase phosphatase (PNKP). The interview, disseminated on behalf of Onco-Innovations, sheds light on a strategy that combines synthetic lethality with nanoparticle delivery to potentially enhance efficacy and reduce toxicity.
Mohamed explained that ONC010 employs two selectivity mechanisms. First, synthetic lethality is designed to limit the drug's lethality to cancer cells that have lost PTEN or SHP-1, two tumor suppressor proteins. This means the drug may preferentially kill cancer cells with these specific genetic defects while sparing healthy cells. Second, nanoparticle delivery is intended to concentrate the drug within tumor tissue, further improving the therapeutic index. These dual mechanisms could address a major challenge in oncology: achieving tumor-specific killing without harming normal tissues.
The scientific rationale is supported by preclinical research at the University of Alberta, where the nano-formulated PNKP inhibitor demonstrated single-agent antitumor activity. According to Mohamed, the drug was tolerated at tested doses and prolonged survival relative to controls. These findings are encouraging as the company prepares for a planned first-in-human clinical program. If the preclinical results translate to humans, ONC010 could offer a new option for patients with cancers that have limited treatment choices.
The importance of this news lies in its potential to validate PNKP as a clinical target. PNKP is an enzyme involved in DNA damage repair, and inhibiting it can overwhelm cancer cells' ability to fix DNA, leading to cell death. By focusing on cancers with PTEN or SHP-1 loss, Onco-Innovations aims to create a precision medicine that is both effective and well-tolerated. This approach aligns with broader trends in oncology toward targeted therapies that exploit specific genetic vulnerabilities.
For industry leaders and investors, Onco-Innovations' progress signals a growing interest in DNA damage response (DDR) therapies. The global market for DDR inhibitors is expanding, with several large pharmaceutical companies investing heavily in this space. Onco-Innovations holds an exclusive worldwide license to patented technology directed to the therapeutic inhibition of PNKP, positioning it as a key player in this niche. The company's ability to advance ONC010 into clinical trials will be a critical milestone to watch.
Moreover, the use of nanoparticle delivery could have implications beyond oncology. If successful, this platform might be adapted for other drugs, potentially improving the delivery of a wide range of therapeutics. However, challenges remain, including scaling up manufacturing and demonstrating safety and efficacy in humans. The upcoming first-in-human trial will be closely monitored by both the scientific community and investors.
To view the full press release, visit https://ibn.fm/XgpMR. The latest news and updates relating to ONNVF are available in the company's newsroom at https://ibn.fm/ONNVF. For more information about BioMedWire, visit https://www.BioMedWire.com.
